AUPH · Aurinia Pharmaceuticals Inc
$17.04
+1.07% last session
End-of-day data · close of 2026-10-26
Market cap
$2B
Enterprise value
$2B
Trailing P/E
7.5
Forward P/E
14.6
Dividend yield
0.0%
Beta
1.61
Avg volume
1M
Employees
0K
Daily Change %
1.07%
5 Days Change
-1.67%
10 Days Change
3.21%
30 Days Change
3.65%
60 Days Change
4.60%
Month to Day Change
6.83%
Year to Day Change
6.83%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — AUPH
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-21
Latest call per bank · past 12 months
RBC Capital
Sector Perform$16.00
-6.1% vs priceJefferies
Buy$21.00
+23.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | TD Cowen | Maintains | Buy | $17.00 → $18.00 |
| 2026-08-07 | RBC Capital | Maintains | Sector Perform | $15.00 → $16.00 |
| 2025-12-03 | Leerink Partners | Downgrade | Outperform → Market Perform | $15.00 → $16.00 |
| 2025-11-07 | Jefferies | Upgrade | Hold → Buy | $10.00 → $21.00 |
| 2025-11-05 | RBC Capital | Downgrade | Outperform → Sector Perform | $9.00 → $15.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 59 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 3.9% above the 50-day MA ($16.40).
- bullish: Price vs 200-day MA: Trading 9.2% above the 200-day MA ($15.61).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.07) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($11.89) and high ($18.62).
AUPH Price Chart
Loading chart for AUPH…
Fundamentals
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.